title: Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials.
abstract: Given increasing resistance, therapeutic options to treat MRSA soft tissue infections should be evaluated. This pooled analysis evaluated data from subjects enrolled in 6 tigecycline clinical trials with documented MRSA complicated skin and skin structure infections or diabetic foot infections (DFIs). Baseline characteristics were compared between subjects with and without molecularly classified community-acquired (CA) MRSA, specifically staphylococcal cassette chromosome mec (SCCmec) IV. Clinical response was compared by CA-MRSA designation and treatment group. A total of 378 subjects with MRSA soft tissue infections were identified, including 79 with DFI. A total of 249 (65.9%) were molecularly classified as CA-MRSA. Clinical response rates for MRSA soft tissue infection were similar between tigecycline and vancomycin (treatment difference, 1.0%; 95% confidence interval: -9.3, 12.0) as well as by infection type, SCCmec, and Panton-Valentine leukocidin (PVL) status. Tigecycline demonstrated comparable efficacy for treatment of MRSA soft tissue infections regardless of infection type, SCCmec, or PVL status.
authors.affiliation: Pfizer Inc, Collegeville, PA, USA. Electronic address: LauraPuzniak@yahoo.com.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Puzniak
authors.affiliation: Pfizer Inc, Collegeville, PA, USA.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Quintana
authors.affiliation: Pfizer Inc, Collegeville, PA, USA.
authors.forename: Michele
authors.initials: M
authors.lastname: Wible
authors.affiliation: Pfizer Inc, Collegeville, PA, USA.
authors.forename: Tim
authors.initials: T
authors.lastname: Babinchak
authors.affiliation: Pfizer Inc, Collegeville, PA, USA.
authors.forename: Paul C
authors.initials: PC
authors.lastname: McGovern
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017719:Diabetic Foot / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058889:Molecular Typing; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline
keywords: Complicated skin and skin structure infections; Diabetic foot infections; Methicillin-resistant Staphylococcus aureus; Tigecycline